Profitability
Weight: 15%
D-
30
- 5yr Avg ROIC -38.1%
- Operating Margin Trend +1109.05 pp/yr
TSHA
Taysha Gene Therapies, Inc.
AlphaQuality composite grade, weighted for high-growth software businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -52.7%
- 5yr Share-Count CAGR 70.7%
Growth Quality
Weight: 35%
C+
60
- 5yr Revenue CAGR 57.5%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 2/5
Cash Generation
Weight: 20%
F
0
- 5yr FCF Margin -1746.6%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 10%
F
25
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) -1729.08x
- Altman Z-Score 5.52
Stability
Weight: 5%
B+
75
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 3
- Negative-Revenue Years (5) 1/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.2 of 3 gurus held; 1 added; 1 trimmed; 1 full exit.
- Holders
- 2 -1
- Avg Δ position
- -38.9%
- New buys
- 0
- Full exits
- 1